Efficacy and safety of roxadustat for the treatment of renal anemia in patients undergoing peritoneal dialysis: a systematic review and meta-analysis.
Yuanyuan Zhou, Jianshan Liao, Wenrui Huang et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy and safety of roxadustat for treating renal anemia in patients undergoing peritoneal dialysis. Nineteen randomized controlled studies with 1,636 participants were analyzed. Roxadustat-based regimens resulted in a higher average post-treatment hemoglobin level compared to ESA-based regimens, with a mean difference of 7.30 g/L.
Key findings
- Average post-treatment hemoglobin level was 7.30 g/L higher in roxadustat groups compared to ESA groups.
- The pooled adverse-event rate for roxadustat showed a relative risk of 0.45.
- Hematocrit and red blood cell count also differed significantly between treatment groups.
- Evidence quality for hemoglobin outcomes was graded as low.
Why it matters
Understanding the comparative effectiveness of roxadustat versus traditional ESA therapies is crucial for optimizing anemia management in patients on peritoneal dialysis, a common complication in this population.
What to keep in mind
Definitions and ascertainment of adverse events were not standardized, and evidence quality was low for many outcomes.